Company Overview: Catalyst Biosciences

Industry News

6 Sep

Catalyst Biosciences Announces Positive Factor IX Clinical Data

— CB 2679d/ISU304 is approximately 22 times more potent than current hemophilia B therapy — SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), today announced positive clinical data from the first Cohort of its ongoing Phase 1/2 proof-of-concept clinical trial in individuals with...

Read more

6 Jul

Financial Milestone Achieved in Catalyst’s Subcutaneous Factor IX Program

SOUTH SAN FRANCISCO, Calif., July 06, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that it has achieved a financial milestone under its collaboration with ISU Abxis. In June of 2017, the first patient...

Read more

28 Jun

Catalyst Biosciences’ Factor IX Granted Orphan Drug Designation in Europe

SOUTH SAN FRANCISCO, Calif., June 28, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that the European Commission has granted orphan medicinal product designation to CB 2679d/ISU304, a clinical stage drug candidate for hemophilia B....

Read more

26 Jun

Catalyst Biosciences Announces Achievement of Stable Normal Factor IX Blood Levels in a Preclinical Subcutaneous Dosing Model

— Data support ongoing clinical trial in individuals with hemophilia B — — Data to be presented at ISTH oral session Future Biotherapeutics for Hemophilia A and B — SOUTH SAN FRANCISCO, Calif., June 26, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel...

Read more

14 Jun

Catalyst Biosciences and ISU Abxis Complete Dosing of First Patient Cohort in Hemophilia B Clinical Trial

SOUTH SAN FRANCISCO, Calif. and SEOUL, South Korea, June 14, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, and ISU Abxis Co Ltd. (086890.KQ) a commercial-stage biopharmaceutical company and Catalyst’s collaborator in the development of its...

Read more

31 May

Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe

SOUTH SAN FRANCISCO, Calif., May 31, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending orphan medicinal...

Read more

Page 1 of 3123

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address